WO2003049747A1 - Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung - Google Patents
Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung Download PDFInfo
- Publication number
- WO2003049747A1 WO2003049747A1 PCT/DE2002/004527 DE0204527W WO03049747A1 WO 2003049747 A1 WO2003049747 A1 WO 2003049747A1 DE 0204527 W DE0204527 W DE 0204527W WO 03049747 A1 WO03049747 A1 WO 03049747A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- eye
- hyaluronate
- composition according
- hyaluronic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to a pharmaceutical composition and its use for the treatment of ophthalmic and rhinological malfunctions.
- the clinical picture of the "dry eye” is also called Sicca syndrome or Sicca symptoms.
- the clinical picture of the "dry eye”, the symptoms of which are expressed in, among other things, burning, scratching, feeling of sand grain in the eye and blurred vision, is due to functional disorders of the tear film.
- the clinical picture of the "dry eye” can also be attributed to a reduced flow of tears, which can have various pathological causes. Due to the reduced flow of tears, only insufficient or no tear film can form on the surface of the eye. The tear film acts as a lubricant or lubricant between the eyelid and the surface of the eye. Due to the missing or insufficient tear film, it can lead to considerable trauma to the epithelial layers.
- the object of the present invention is to provide a pharmaceutical composition which allows better therapy of diseases of the eye, which are associated in particular with functional disorders of the tear film or with a reduced flow of tears.
- the object is achieved by providing a pharmaceutical composition which comprises at least panthenol and / or pantothenic acid and hyaluronic acid and / or hyaluronate and, if appropriate, additional pharmaceutical auxiliaries.
- Drying of the nasal mucosa can also affect medication, e.g. continuous use of decongestant colds is caused.
- the pharmaceutical composition is preferably provided in the form of a nose or eye spray or in the form of nose or eye drops.
- the hyaluronic acid and / or the hyaluronate and the panthenol and or the pantothenic acid are dissolved in aqueous solutions.
- Chondroitin sulfate, polyacrylic acid, polyacrylic acid, polyacrylic resins, polyethylene glycol, cellulose derivatives, polyvinyl alcohol, polyvinylpyrrolidone or mixtures thereof can be used as viscosity regulators.
- the molecular chains are randomly arranged in a coil. Under the influence of the shear forces exerted by the movement of the eye eye, the macromolecules align approximately in parallel. This change in the three-dimensional structure under the influence of shear forces is likely to be decisive for the excellent viscoelastic properties.
- the amount of hyaluronic acid and / or the amount of hyaluronate is about 0.005% by weight to about
- the amount of hyaluronic acid and / or the amount of hyaluronate is particularly preferably about 0.05% by weight to about 0.5% by weight, based on the total weight of the pharmaceutical formulation.
- Hyaluronic acid or hyaluronates are extremely advantageous in that they bind water. This property of binding water is particularly advantageous in the treatment of Sicca syndrome, since it counteracts the undesirable drying out of the cornea of the eye. Concentrations of 0.1% by weight to 0.3% by weight, based on the total weight of the pharmaceutical formulation, hyaluronic acid and / or hyaluronate have proven to be very suitable.
- “Dry eye” is the tear film tear time, which allows a statement about the quality of the tear fluid. For example, the tear film is stained with fluorescein and the patient is then asked to keep the eyes open for as long as possible without the blinking reflex. Using a slit lamp, it is then determined when the tear film opens for the first time. If the period is less than 10 seconds, there is a suspicion of the clinical picture of the "dry eye".
- Hyaluronic acid in a concentration of 0.1% by weight to 0.3% by weight, based on the total weight of the pharmaceutical formulation has proven to be very effective in terms of extending the tear film tear-open time.
- the simultaneous action of panthenol and / or pantothenic acid and the provision of an artificial tear film leads to a synergistic effect, which allows faster treatment of epithelial lesions, in particular in the clinical picture of the "dry eye”.
- panthenol and / or pantothenic acid and hyaluronic acid and / or hyaluronate leads to rapid epithelialization.
- the extremely unpleasant itching sensation that occurs with epithelial lesions on the eye is quickly relieved.
- the pharmaceutical composition according to the invention is therefore a combination of drugs.
- the hyaluronic acid and / or the hyaluronate have very suitable viscoelastic properties for use on the surface of the eye due to the non-Newtonian flow behavior.
- the non-Newtonian flow behavior delays the outflow of the pharmaceutical composition applied to the eye and thus extends the contact with the cornea of the eye.
- the panthenol and / or the pantothenic acid can be kept on the cornea over a longer period of time, for example from at least 30 minutes to at least 60 minutes.
- panthenol and / or the pantothenic acid therefore have an extremely advantageous effect on the surface of the eye over the entire duration of the treatment.
- the dosage of panthenol and / or pantothenic acid can advantageously be reduced in the therapy and, on the other hand, the treatment time can be shortened.
- the amount of panthenol and / or the pantothenic acid is about 0.5% by weight to 10% by weight, preferably about 2% by weight to 5% by weight, based on the total weight of the pharmaceutical composition .
- An amount of about 3% by weight, based on the total weight of the pharmaceutical composition, has proven to be very suitable.
- the panthenol is present as D - (+) - 2,4-dihydroxy-N- (3-hydroxypropyl) -3,3-dimethylbutyramide.
- This clockwise D configuration is also known as dexpanthenol.
- the pharmaceutical composition is in the form of a solution, suspension, emulsion, a gel, an ointment, paste, a powder, granules or a tablet, which can preferably be used directly on the eye or applied to the surface of the eye.
- the pharmaceutical composition is in the form of a solution, so that it can be applied to the corneal surface of the eye, for example in the form of eye drops or an eye spray.
- a preservative-free pharmaceutical composition according to the invention in the "PTA today" 1996 no is preferably used for storage and dispensing. 12, pp 1230-1232 described COMOD ® system is used, which allows sterile storage and multiple dispensing of the pharmaceutical composition of the invention. Of course, conventional single-dose containers that are thrown away after use can also be used.
- the pharmaceutical composition is preferably provided free of preservatives.
- the pharmaceutical composition is preferably applied to the eye in the form of eye drops.
- the active ingredients are provided, for example, in petroleum jelly or paraffin with and without the addition of an emulsifier, such as cholesterol, wool wax, wool wax alcohols, cetanol, etc.
- the object on which the invention is based is further achieved by using a pharmaceutical composition according to one of Claims 1 to 8 for the treatment of ophthalmological and / or rhinological malfunctions.
- the pharmaceutical composition according to one of claims 1 to 8 is preferably used for the treatment of ophthalmic malfunctions which are associated with wetting disorders of the cornea of the eye.
- the pharmaceutical composition is further preferably used for the treatment of allergic rhinoconjunctivitis, atopic keratoconjunctivitis, allergic keratoconjunctivitis, gigantopapillary conjunctivitis, conjunctivitis vernalis, episcleritis, such as episcleritis periodica, episcleritis partialis fax, scleritis or mixed grenonitis syndrome, S.
- the pharmaceutical composition according to one of claims 1 to 8 is preferably used for the treatment of rhinological malfunctions which are associated with symptoms of dehydration of the nasal mucosa.
- the pharmaceutical composition is more preferably used for the treatment of chronic rhinitis, rhinitis sicca, rhinitis sicca anterior or mixed forms thereof.
- composition for ophthalmological and rhinological application
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003550796A JP3994089B2 (ja) | 2001-12-12 | 2002-12-11 | 眼科学および鼻科学における適用のための薬学的組成物 |
AT02794984T ATE300306T1 (de) | 2001-12-12 | 2002-12-11 | Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung |
ES02794984.1T ES2244831T5 (es) | 2001-12-12 | 2002-12-11 | Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica |
CA002468771A CA2468771C (en) | 2001-12-12 | 2002-12-11 | Pharmaceutical composition for use in ophthalmology and rhinology |
MXPA04005387A MXPA04005387A (es) | 2001-12-12 | 2002-12-11 | Composicion farmaceutica para uso en oftalmologia y rinologia. |
EP02794984.1A EP1455803B2 (de) | 2001-12-12 | 2002-12-11 | Verwendung von panthenol und/oder panthothensäure und hyaluronsäure/und oder hyaluronat zur herstellung einer pharmazeutischen zusammensetzung zur ophtalmologischen anwendung |
AU2002360895A AU2002360895A1 (en) | 2001-12-12 | 2002-12-11 | Pharmaceutical composition for use in ophthalmology and rhinology |
US10/496,456 US20050164979A1 (en) | 2001-12-12 | 2002-12-11 | Pharmaceutical composition for ophthalmological and rhinological application |
DE50203788T DE50203788D1 (de) | 2001-12-12 | 2002-12-11 | Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10161110.2 | 2001-12-12 | ||
DE10161110A DE10161110A1 (de) | 2001-12-12 | 2001-12-12 | Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003049747A1 true WO2003049747A1 (de) | 2003-06-19 |
WO2003049747A8 WO2003049747A8 (de) | 2003-10-02 |
Family
ID=7708986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2002/004527 WO2003049747A1 (de) | 2001-12-12 | 2002-12-11 | Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung |
Country Status (11)
Country | Link |
---|---|
US (1) | US20050164979A1 (de) |
EP (1) | EP1455803B2 (de) |
JP (1) | JP3994089B2 (de) |
CN (1) | CN1310651C (de) |
AT (1) | ATE300306T1 (de) |
AU (1) | AU2002360895A1 (de) |
CA (1) | CA2468771C (de) |
DE (2) | DE10161110A1 (de) |
ES (1) | ES2244831T5 (de) |
MX (1) | MXPA04005387A (de) |
WO (1) | WO2003049747A1 (de) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1532986A2 (de) | 2003-11-13 | 2005-05-25 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH | Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden |
WO2006066500A1 (fr) * | 2004-12-20 | 2006-06-29 | Peixue Ling | Procédé de synthèse de dérivés de quinazoline et application à la fabrication d'un médicament pour le traitement d'une maladie de type tumoral |
EP1711190A1 (de) | 2004-01-14 | 2006-10-18 | Johannes Reinmüller | Mittel zur behandlung von entz ndlichen erkrankungen |
WO2008011836A2 (es) | 2006-07-25 | 2008-01-31 | Osmotica Corp. | Soluciones oftálmicas |
EP2167102A2 (de) | 2007-07-23 | 2010-03-31 | Agro Industrie Recherches Et Developpements A.R.D. | Verwendung von hyaluronsäure zur herstellung von zusammensetzungen insbesondere zur verbesserung der funktion der haut und der augen sowie zum schutz der mukosemembran |
EP2664330A1 (de) * | 2012-05-15 | 2013-11-20 | F. Holzer GmbH | Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan |
WO2013170921A1 (de) * | 2012-05-14 | 2013-11-21 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Kombinationstherapeutikum für die behandlung von rhinitis |
EP3072503A1 (de) | 2015-03-26 | 2016-09-28 | D.M.G. Italia Srl | Ophthalmische zusammensetzung für hornhautgewebe |
WO2017153415A1 (de) * | 2016-03-07 | 2017-09-14 | Ursapharm Arzneimittel Gmbh | Ophthalmologische zusammensetzung |
WO2019025040A1 (de) * | 2017-07-31 | 2019-02-07 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Zusammensetzung für die nasale applikation |
WO2019202017A1 (en) * | 2018-04-18 | 2019-10-24 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
EP2985027B1 (de) | 2014-08-16 | 2021-03-31 | Church & Dwight Co., Inc. | Nasenheilmittel enthaltend ein gemisch von hyaluronsäuren und salzlösung |
EP2985019B1 (de) | 2014-08-16 | 2021-10-20 | Church & Dwight Co., Inc. | Nasale Zusammensetzung mit antiviralen Eigenschaften |
EP4039248A1 (de) * | 2021-02-04 | 2022-08-10 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmische zusammensetzung |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005055275A1 (de) | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung |
JP4987078B2 (ja) * | 2006-11-30 | 2012-07-25 | 株式会社メニコン | 眼科用組成物 |
KR100927579B1 (ko) * | 2006-12-13 | 2009-11-23 | 주식회사 엘지생명과학 | 히아루론산 및/또는 그것의 염을 함유하는 아토피성피부염의 개선 및 치료를 위한 조성물 |
DE202008016517U1 (de) * | 2008-12-12 | 2009-03-05 | Ratiopharm Gmbh | Wässrige Zusammensetzung enthaltend Dexpanthenol und Natriumchlorid |
US9473792B2 (en) | 2009-11-06 | 2016-10-18 | Texas Instruments Incorporated | Method and system to improve the performance of a video encoder |
FR2962044B1 (fr) * | 2010-04-21 | 2013-02-22 | Horus Pharma | Emulsion lacrymimetique |
SG186782A1 (en) * | 2010-07-02 | 2013-02-28 | Holden Brien Vision Inst | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease |
DE202010012255U1 (de) * | 2010-09-07 | 2010-11-18 | Krewel Meuselbach Gmbh | Nasenspray |
WO2012119261A1 (en) * | 2011-03-10 | 2012-09-13 | Biocia Inc. | Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis |
CN102579478A (zh) * | 2012-03-30 | 2012-07-18 | 济南康众医药科技开发有限公司 | 玻璃酸钠在制备药物中的应用 |
CN102989045B (zh) * | 2012-11-12 | 2015-02-25 | 广州共禾医药科技有限公司 | 生物相容的水性组合物及其用途 |
MX2017001812A (es) * | 2014-08-08 | 2017-07-17 | Shenzhen Hightide Biopharmaceutical Ltd | Composiciones de formulacion liquida, aparatos de administracion de medicamentos, y metodos de preparacion y uso de los mismos. |
DE102016204472A1 (de) * | 2016-03-17 | 2017-09-21 | Ursapharm Arzneimittel Gmbh | Kit zur kosmetischen Behandlung des Auges und der Haut und Kosmetikum zur Anwendung am Auge und auf der Haut |
TWI609957B (zh) | 2016-06-27 | 2018-01-01 | 晶碩光學股份有限公司 | 用以處理隱形眼鏡之溶液及隱形眼鏡的包裝系統 |
JP7044467B2 (ja) * | 2017-01-16 | 2022-03-30 | ロート製薬株式会社 | 眼科組成物 |
CN107260657B (zh) * | 2017-08-03 | 2019-02-05 | 广东莱恩医药研究院有限公司 | 一种缓释型连翘苷滴眼液及其制备方法 |
US20200246311A1 (en) * | 2017-08-10 | 2020-08-06 | Elixir Ilac Arastirma Ve Gelistirme A.S. | Nasal decongestant compositions comprising dexpanthenol and sodium hyaluronate |
KR20210003168A (ko) * | 2018-04-18 | 2021-01-11 | 이콤 메디칼 게엠베하 | 상피 생존의 증대 및 체표면의 재구성을 위한 고분자량 히알루론산 |
WO2020053783A1 (en) * | 2018-09-12 | 2020-03-19 | Neilos S.r.l. | A composition for use in the prevention and/or treatment of epistaxis |
EP3827818A1 (de) * | 2019-11-26 | 2021-06-02 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmische zusammensetzung |
CN112870216A (zh) * | 2021-01-29 | 2021-06-01 | 张宽才 | 一种药物组合物及制剂和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
DE19923829A1 (de) * | 1999-05-17 | 2000-11-23 | Ulrich Kluegel | Hyaluronat-Wirkstoff-Wasser-Komplex, dessen Herstellung und Verwendung |
WO2002060495A1 (en) * | 2001-01-09 | 2002-08-08 | Louis Johan Wagenaar | Procedure and composition of treatment and/or care of the eye |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6479103A (en) * | 1987-06-09 | 1989-03-24 | Lion Corp | External preparation |
DE3832401A1 (de) † | 1988-09-23 | 1990-03-29 | Cassella Ag | Pharmazeutische zubereitung zur behandlung entzuendeter nasenschleimhaeute |
US5141741A (en) * | 1988-12-09 | 1992-08-25 | Lion Corporation | Anti-sunburn skin-care preparation |
IL101056A (en) † | 1992-02-24 | 1997-03-18 | Res & Dev Co Ltd | Composition for nasal treatment |
IT1273011B (it) * | 1994-07-25 | 1997-07-01 | Trhecnopharma S A | Preparato oftalmico per l'uso come lacrima artificiale |
DE19517251A1 (de) * | 1995-05-11 | 1996-11-14 | Klosterfrau Mcm Vetrieb Gmbh | Verwendung von Dexpanthenol zur Behandlung trockener Nasenschleimhäute |
DE19549421C2 (de) † | 1995-11-10 | 1999-11-18 | Klosterfrau Mcm Vetrieb Gmbh | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden |
DE19541919C2 (de) † | 1995-11-10 | 1997-11-20 | Klosterfrau Mcm Vetrieb Gmbh | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden |
TWI285644B (en) * | 1997-07-11 | 2007-08-21 | Toray Industries | A stable pharmaceutical composition containing a derivative of 4,5-epoxymorphinan and a water-soluble antioxidant, an oil-soluble antioxidant, a synergist, a sugar and a surfactant |
-
2001
- 2001-12-12 DE DE10161110A patent/DE10161110A1/de not_active Ceased
-
2002
- 2002-12-11 AT AT02794984T patent/ATE300306T1/de active
- 2002-12-11 WO PCT/DE2002/004527 patent/WO2003049747A1/de active IP Right Grant
- 2002-12-11 JP JP2003550796A patent/JP3994089B2/ja not_active Expired - Lifetime
- 2002-12-11 CA CA002468771A patent/CA2468771C/en not_active Expired - Lifetime
- 2002-12-11 US US10/496,456 patent/US20050164979A1/en not_active Abandoned
- 2002-12-11 DE DE50203788T patent/DE50203788D1/de not_active Expired - Lifetime
- 2002-12-11 AU AU2002360895A patent/AU2002360895A1/en not_active Abandoned
- 2002-12-11 EP EP02794984.1A patent/EP1455803B2/de not_active Expired - Lifetime
- 2002-12-11 ES ES02794984.1T patent/ES2244831T5/es not_active Expired - Lifetime
- 2002-12-11 CN CNB028248309A patent/CN1310651C/zh not_active Expired - Lifetime
- 2002-12-11 MX MXPA04005387A patent/MXPA04005387A/es active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
DE19923829A1 (de) * | 1999-05-17 | 2000-11-23 | Ulrich Kluegel | Hyaluronat-Wirkstoff-Wasser-Komplex, dessen Herstellung und Verwendung |
WO2002060495A1 (en) * | 2001-01-09 | 2002-08-08 | Louis Johan Wagenaar | Procedure and composition of treatment and/or care of the eye |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1532986A2 (de) | 2003-11-13 | 2005-05-25 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH | Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden |
EP1532986A3 (de) * | 2003-11-13 | 2005-07-20 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH | Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden |
EP1711190A1 (de) | 2004-01-14 | 2006-10-18 | Johannes Reinmüller | Mittel zur behandlung von entz ndlichen erkrankungen |
US7902171B2 (en) | 2004-01-14 | 2011-03-08 | Reinmueller Johannes | Composition for treating inflammatory diseases |
WO2006066500A1 (fr) * | 2004-12-20 | 2006-06-29 | Peixue Ling | Procédé de synthèse de dérivés de quinazoline et application à la fabrication d'un médicament pour le traitement d'une maladie de type tumoral |
WO2008011836A2 (es) | 2006-07-25 | 2008-01-31 | Osmotica Corp. | Soluciones oftálmicas |
EP2167102A2 (de) | 2007-07-23 | 2010-03-31 | Agro Industrie Recherches Et Developpements A.R.D. | Verwendung von hyaluronsäure zur herstellung von zusammensetzungen insbesondere zur verbesserung der funktion der haut und der augen sowie zum schutz der mukosemembran |
CN101801391B (zh) * | 2007-07-23 | 2013-07-10 | 农业工业研究发展公司 | 透明质酸在制备用于改善皮肤、眼和粘膜的保护功能的组合物中的用途 |
WO2013170921A1 (de) * | 2012-05-14 | 2013-11-21 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Kombinationstherapeutikum für die behandlung von rhinitis |
EP2822537B1 (de) | 2012-05-14 | 2015-12-09 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH | Kombinationstherapeutikum für die behandlung von rhinitis |
EA030042B1 (ru) * | 2012-05-14 | 2018-06-29 | Мария Клементине Мартин Клостерфрау Фертрибсгезелльшафт Мбх | Комбинированное терапевтическое средство для лечения ринита |
EP2664330A1 (de) * | 2012-05-15 | 2013-11-20 | F. Holzer GmbH | Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan |
WO2013171203A1 (de) * | 2012-05-15 | 2013-11-21 | F. Holzer Gmbh | Fluidspender enthaltend eine ophthalmologische zusammensetzung |
EP2985027B1 (de) | 2014-08-16 | 2021-03-31 | Church & Dwight Co., Inc. | Nasenheilmittel enthaltend ein gemisch von hyaluronsäuren und salzlösung |
EP2985019B1 (de) | 2014-08-16 | 2021-10-20 | Church & Dwight Co., Inc. | Nasale Zusammensetzung mit antiviralen Eigenschaften |
EP3072503A1 (de) | 2015-03-26 | 2016-09-28 | D.M.G. Italia Srl | Ophthalmische zusammensetzung für hornhautgewebe |
RU2749723C2 (ru) * | 2016-03-07 | 2021-06-16 | Урзафарм Арцнаймиттель Гмбх | Офтальмологическая композиция |
WO2017153415A1 (de) * | 2016-03-07 | 2017-09-14 | Ursapharm Arzneimittel Gmbh | Ophthalmologische zusammensetzung |
EP3426226B1 (de) | 2016-03-07 | 2022-05-04 | URSAPHARM Arzneimittel GmbH | Ophthalmologische zusammensetzung |
WO2019025040A1 (de) * | 2017-07-31 | 2019-02-07 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Zusammensetzung für die nasale applikation |
WO2019202017A1 (en) * | 2018-04-18 | 2019-10-24 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
EP4039248A1 (de) * | 2021-02-04 | 2022-08-10 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmische zusammensetzung |
WO2022167569A1 (en) * | 2021-02-04 | 2022-08-11 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic composition |
Also Published As
Publication number | Publication date |
---|---|
JP2006501133A (ja) | 2006-01-12 |
JP3994089B2 (ja) | 2007-10-17 |
DE50203788D1 (de) | 2005-09-01 |
MXPA04005387A (es) | 2005-03-23 |
WO2003049747A8 (de) | 2003-10-02 |
ES2244831T3 (es) | 2005-12-16 |
ATE300306T1 (de) | 2005-08-15 |
EP1455803A1 (de) | 2004-09-15 |
ES2244831T5 (es) | 2016-05-10 |
EP1455803B2 (de) | 2016-03-23 |
CA2468771C (en) | 2007-01-30 |
CN1310651C (zh) | 2007-04-18 |
AU2002360895A1 (en) | 2003-06-23 |
EP1455803B1 (de) | 2005-07-27 |
CN1602198A (zh) | 2005-03-30 |
CA2468771A1 (en) | 2003-06-19 |
US20050164979A1 (en) | 2005-07-28 |
DE10161110A1 (de) | 2003-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1455803B1 (de) | Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung | |
EP2214658B1 (de) | Osmolythaltige zubereitung zur anwendung bei trockenen schleimhäuten | |
DE69527765T2 (de) | Verwendung von Hyaluronsäure oder sein Salz zur Behandlung von Hauterkrankungen | |
EP1453523B1 (de) | Heparin-haltiges ophthalmikum | |
EP2613793B1 (de) | Nasenspray | |
EP2099462B1 (de) | Pharmazeutische zubereitung für die behandlung entzündlicher erkrankungen des urogenitaltraktes | |
EP1948131B3 (de) | Dexpanthenol-, calciumionen- und phosphatfreie pharmazeutische zusammensetzung sowie verwendung von calcium-chelatbildner und ophthalmologisch verträglichem viskositätsregler | |
DE69434992T2 (de) | Hyaluronsäure und deren derivate enthaltende arzneimittel zur topischen anwendung | |
WO1988010121A1 (en) | Use of a drug to treat the eye and suitable carrier material | |
CH685099A5 (de) | Pharmazeutisches Präparat für die intranasale Anwendung. | |
EP0773022A2 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure | |
DE60017175T2 (de) | Ciclesonidhaltige arzneizusammensetzung zur verabreichung auf die schleimhäute | |
DE60205913T2 (de) | Ophthalmische zubereitung mit n-acetylcystein zur behandlung trockener augen | |
DE102008036725B4 (de) | Pharmazeutische Zusammensetzung für die nasale Applikation | |
DE69000295T2 (de) | Therapeutische zusammensetzung zur behandlung oder verhuetung des schnarchens. | |
DE3818094C1 (de) | ||
DE202006005924U1 (de) | Zusammensetzung zur Behandlung von Rhinitis | |
DE10360425A1 (de) | Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung | |
WO2017129457A1 (de) | Pharmazeutische zubereitung und deren verwendung bei viralen, entzündlichen erkrankungen der oberen atemwege | |
CH690023A5 (de) | Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut. | |
DE102004008375B4 (de) | Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002794984 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2468771 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/005387 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028248309 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003550796 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002794984 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10496456 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002794984 Country of ref document: EP |